乳腺癌组织中TET2突变与5hmC表达的关系

被引：2

作者：

顾盼盼 ^{[1
]}

罗欣 ^{[1
]}

张宏伟 ^{[2
]}

谭理 ^{[1
]}

陈浩 ^{[1
]}

孔令春 ^{[1
]}

刁建波 ^{[1
]}

石雨江 ^{[1
]}

马端 ^{[1
]}

机构：

[1] 复旦大学生物医学研究院

[2] 复旦大学附属中山医院普外科

来源：

中国临床医学 | 2015年 / 22卷 / 01期

关键词：

TET2; 乳腺癌; 5-羟甲基胞嘧啶; 突变;

D O I：

暂无

中图分类号：

R737.9 [乳腺肿瘤];

学科分类号：

摘要：

目的:探讨乳腺癌组织中TET2(ten-eleven translocation 2)基因的突变与5-羟甲基胞嘧啶(5hmC)表达的关系。方法:收集100例乳腺癌患者的癌组织标本。用Sanger方法检测乳腺癌组织中的TET2突变情况;用免疫组化方法检测乳腺癌组织中5hmC的表达情况;分析TET2突变与5hmC表达的关系。结果:100例乳腺癌组织中有13种TET2突变,在4例患者的肿瘤组织中发现3种以前未报道过的TET2突变(Ala341Val、Leu1622Phe、Pro1578Tyr),在2例患者的肿瘤组织中均检测到Pro1578Tyr突变。免疫组化结果显示,有TET2突变的乳腺癌组织中的5hmC表达明显低于无TET2突变的乳腺癌组织。结论:乳腺癌中TET2突变导致5hmC水平下降。

引用

页码：1 / 4

页数：4

共 10 条

[1] Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China[J] . Lei Fan,Ying Zheng,Ke-Da Yu,Guang-Yu Liu,Jiong Wu,Jin-Song Lu,Kun-Wei Shen,Zhen-Zhou Shen,Zhi-Ming Shao. &nbspBreast Cancer Research and Treatment . 2009 (2)
[2] Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Haffner Michael C,Chaux Alcides,Meeker Alan K,Esopi David M,Gerber Jonathan,Pellakuru Laxmi G,Toubaji Antoun,Argani Pedram,Iacobuzio-Donahue Christine,Nelson William G,Netto George J,De Marzo Angelo M,Yegnasubramanian Srinivasan. Oncotarget . 2011
[3] Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. A Tefferi,K-H Lim,O Abdel-Wahab,T L Lasho,J Patel,M M Patnaik,C A Hanson,A Pardanani,D G Gilliland,R L Levine. Leukemia . 2009
[4] Conversion of5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNAby MLL partner TET1. Tahiliani M,Koh K P,Shen Y,et al. Science . 2009
[5] Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Abdel-Wahab Omar,Mullally Ann,Hedvat Cyrus,Garcia-Manero Guillermo,Patel Jay,Wadleigh Martha,Malinge Sebastien,Yao JinJuan,Kilpivaara Outi,Bhat Rukhmi,Huberman Kety,Thomas Sabrena,Dolgalev Igor,Heguy Adriana,Paietta Elisabeth,Le Beau Michel. Blood . 2009
[6] Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Jankowska Anna M,Szpurka Hadrian,Tiu Ramon V,Makishima Hideki,Afable Manuel,Huh Jungwon,O’Keefe Christine L,Ganetzky Rebecca,McDevitt Michael A,Maciejewski Jaroslaw P. Blood . 2009
[7] Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. A Tefferi,R L Levine,K-H Lim,O Abdel-Wahab,T L Lasho,J Patel,C M Finke,A Mullally,C-Y Li,A Pardanani,D G Gilliland. Leukemia . 2009
[8] Common 4q24 deletion in four cases of hematopoietic malignancy: early stem cell involvement?. F Viguié,A Aboura,D Bouscary,S Ramond,A Delmer,G Tachdjian,J P Marie,N Casadevall. Leukemia . 2005
[9] TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). R B Lorsbach,J Moore,S Mathew,S C Raimondi,S T Mukatira,J R Downing. Leukemia . 2003
[10] Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Yang H,Liu Y,Bai F, et al. Oncegene . 2013

← 1 →